I accept that people can have different sensitivities when it comes to foisting unproven interventions on an unsuspecting public. I'm guessing yours is "but there's a white paper". Noted.
So, presumably, the test should only ever be sold and marketed to people who meet those fairly exacting criteria, if at all?
-
-
No - that is the group that the score is *most* useful for. It's a personal value judgement for the individual. Although yes - I would say on the marketing side it should be clear how well the test would perform across various groups - which is exactly what was done.
-
But what you're saying is that in the best case scenario the test - for people who are low on every other risk, resemble 23andMe userbase, and score in the highest risk tier - will inform people of a risk increase of, what, about 0.05%? Roughly?
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.